Cereno Scientific: First-patient-in and updated study timeline - Redeye

Redeye is encouraged by Cereno Scientific announcing first-patient-in for its phase II study with lead candidate CS1 in PAH. Further, the company updated its guidance on top-line data, now expected in Q1 2023 (Q4 2022).

Länk till analysen i sin helhet: https://www.redeye.se/research/848158/cereno-scientific-first-patient-in-and-updated-study-timeline?utm_source=finwire&utm_medium=RSS